Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.

ABSTRACT:

Importance

Preliminary cost-effectiveness analyses of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) were based on benefits estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials with variable results. The recent Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial provides better information about the effectiveness of the drug.

Objective

To use the trial results to determine the cost-effectiveness of a PCSK9i and statin treatment strategy compared with a statin alone strategy.

Design, setting, and participants

We derived observed rates of events, outcomes, cost of care, and health insurance from existing literature for a theoretical cohort of patients d

SUBMITTER: Arrieta A 

PROVIDER: S-EPMC5814995 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature